New typhoid conjugate vaccines offer important advantages over prior vaccines, including the ability to protect young children, longer lasting protection, and the potential to be a part of routine immunization of infants.

This past weekend, leaders of the world’s major economies gathered in Hamburg, Germany, for this year’s G20 Summit. Among the issues on the agenda: safeguarding against health crises and strengthening health systems.

Dr. Jan Holmgren Receives 2017 Albert B. Sabin Gold Medal Award

WASHINGTON, D.C. – April 25, 2017 – Tonight, the Sabin Vaccine Institute (Sabin) will honor Dr. Jan Holmgren with the 2017 Albert B. Sabin Gold Medal Award. Dr. Holmgren will be recognized for his pioneering contributions to oral vaccine research and mucosal immunology, as well as his leadership in the discovery of the world's first effective oral cholera vaccine.

Sabin Vaccine Institute Names Deputy Assistant Secretary for Health as New President of Global Immunization

WASHINGTON, D.C., February 13, 2017 – Sabin Vaccine Institute (Sabin), a non-profit dedicated to making life-improving vaccines more accessible, enabling innovation and expanding immunization across the globe, today announced the appointment of Dr. Bruce Gellin as President, Global Immunization. Dr. Gellin, a 15-year U.S. Department of Health and Human Services (HHS) veteran, has served as Deputy Assistant Secretary for Health and Director of the National Vaccine Program Office since 2002. Among his roles, Dr. Gellin led discussions on behalf of the United States at high-level global and domestic policy advisory groups and was responsible for developing the National Vaccine Plan, our country's blueprint for all aspects of vaccines and immunization.

An estimated two billion people lack the medicines they need. The 2016 Access to Medicines Index analyzes pharmaceutical companies’ efforts to improve access to medicines, vaccines and diagnostics for low- and middle-income countries.

Sabin Vaccine Institute President Dr. Peter Hotez gave the keynote address on NTDs at the Pontifical Council for Health Care Workers’ XXXI International Conference, focused on NTDs and rare diseases.

Sabin PDP Begins Phase 1 Clinical Trial to Co-Administer Two Novel Hookworm Vaccine Candidates in Brazil

WASHINGTON, D.C. — April 28, 2016 — The Sabin Vaccine Institute (Sabin) today announced that its Product Development Partnership (Sabin PDP) began a Phase 1 clinical trial of Na-APR-1 (M74)/Alhydrogel® co-administered with Na-GST-1/Alhydrogel in Brazilian adults.

This article was originally posted on the DSW Blog.

By the Dengue Vaccine Initiative

Pages